(Q36218312)

12 August 2017

1 reference

title

Tigecycline: a new glycylcycline for treatment of serious infections (English)

1 reference

12 August 2017

1

Gary A Noskin

1 reference

PubMed ID

16080069

12 August 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

Clinical Infectious Diseases

12 August 2017

1 reference

12 August 2017

41 Suppl 5

1 reference

12 August 2017

S303-14

1 reference

The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection

12 August 2017

1 reference

Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia

21 January 2018

1 reference

Antimicrobial susceptibility of Gram-positive bacteria: what's current, what's anticipated?

21 January 2018

1 reference

Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002.

21 January 2018

1 reference

In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases

21 January 2018

1 reference

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates

21 January 2018

1 reference

Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA.

21 January 2018

1 reference

Glycylcyclines: third-generation tetracycline antibiotics

21 January 2018

1 reference

The glycylcyclines: a comparative review with the tetracyclines

21 January 2018

1 reference

Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients

21 January 2018

1 reference

Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.

21 January 2018

1 reference

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria

21 January 2018

1 reference

Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936).

21 January 2018

1 reference

In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain

21 January 2018

1 reference

Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens

21 January 2018

1 reference

Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates

21 January 2018

1 reference

In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides

21 January 2018

1 reference

Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus

21 January 2018

1 reference

In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria

21 January 2018

1 reference

In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae

21 January 2018

1 reference

Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002

21 January 2018

1 reference

In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance

21 January 2018

1 reference

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

21 January 2018

1 reference

GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria

21 January 2018

1 reference

Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center

21 January 2018

1 reference

Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia

21 January 2018

1 reference

Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).

21 January 2018

1 reference

In vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates

21 January 2018

1 reference

Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria

21 January 2018

1 reference

In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum

21 January 2018

1 reference

In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis

21 January 2018

1 reference

Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme

21 January 2018

1 reference

Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci

21 January 2018

1 reference

Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis

21 January 2018

1 reference

Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model.

21 January 2018

1 reference

In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm model

21 January 2018

1 reference

Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis

21 January 2018

1 reference

Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination

21 January 2018

1 reference

Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002

21 January 2018

1 reference

AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis

21 January 2018

1 reference

Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

21 January 2018

1 reference

In vitro activities of tigecycline against the Bacteroides fragilis group

21 January 2018

1 reference

Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibil

21 January 2018

1 reference

Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia

21 January 2018

1 reference

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/431672

1 reference

12 August 2017

1 reference

PubMed ID

16080069